Размер шрифта
Цветовая схема
Изображения
Форма
Межсимвольный интервал
Межстрочный интервал
стандартные настройки
обычная версия сайта
закрыть
  • Вход
  • Регистрация
  • Помощь
Выбрать БД
Простой поискРасширенный поискИстория поисков
Главная / Результаты поиска

Prognostic value of testosterone for the castration-resistant prostate cancer patients: a systematic review and meta-analysis

Miura N., Mori K., Mostafaei H., Quhal F., Sari M. R., Abufaraj M., Pradere B., Aydh A., Laukhtina E. A., D’Andrea D., Saika T., Shariat Sh.
International Journal of Clinical Oncology
Опубликовано: 2020
Тип ресурса: Обзор

DOI:10.1007/s10147-020-01747-1

Аннотация:
Introduction: This systematic review and meta-analysis aimed to assess the prognostic value of testosterone in patients with castration-resistant prostate cancer (CRPC). Materials and methods: PubMed, Web of Science, and Scopus databases were systematically searched until December 2019, according to the Preferred Reporting Items for Systemic Review and Meta-analysis statement. The endpoints were progression-free survival (PFS) and overall survival (OS). Results: We identified 11 articles with 4206 patients for systematic review and nine articles with 4136 patients for meta-analysis. Higher testosterone levels were significantly associated with better OS (pooled HR 0.74, 95[%] CI 0.58–0.95) and better PFS (pooled HR 0.51, 95[%] CI 0.30–0.87). Subgroup analyses based on the treatment type revealed that higher testosterone levels were significantly associated with better OS in CRPC patients treated with androgen receptor-targeted agents (ARTAs) (pooled HR 0.64, 95[%] CI 0.55–0.75), but not in t
Ключевые слова:
Androgen receptor-targeted agents; Castration-resistant; Meta-analysis; Prostate cancer; Testosterone
Язык текста: Английский
ISSN: 1437-7772
Miura N.
Mori K.
Mostafaei H.
Quhal F.
Sari M. R. Motlagh R.
Abufaraj M.
Pradere B.
Aydh A.
Laukhtina E. A. Ekaterina Aleksandrovna 1995-
D’Andrea D.
Saika T.
Shariat Sh. Sharokh 1973-
Миура Н.
Мори К.
Мостафаеи Х.
Qухал Ф.
Сари М. Р. Мотлагх Р.
Абуфарай М.
Прадере Б.
Айдх А.
Лаухтина Е. А. Екатерина Александровна 1995-
Д’Андреа Д.
Саика Т.
Шариат Ш. Шарох 1973-
Prognostic value of testosterone for the castration-resistant prostate cancer patients: a systematic review and meta-analysis
Текст визуальный непосредственный
International Journal of Clinical Oncology
Springer-Verlag Tokyo Inc.
Обзор
Androgen receptor-targeted agents Castration-resistant Meta-analysis Prostate cancer Testosterone
Introduction: This systematic review and meta-analysis aimed to assess the prognostic value of testosterone in patients with castration-resistant prostate cancer (CRPC). Materials and methods: PubMed, Web of Science, and Scopus databases were systematically searched until December 2019, according to the Preferred Reporting Items for Systemic Review and Meta-analysis statement. The endpoints were progression-free survival (PFS) and overall survival (OS). Results: We identified 11 articles with 4206 patients for systematic review and nine articles with 4136 patients for meta-analysis. Higher testosterone levels were significantly associated with better OS (pooled HR 0.74, 95[%] CI 0.58–0.95) and better PFS (pooled HR 0.51, 95[%] CI 0.30–0.87). Subgroup analyses based on the treatment type revealed that higher testosterone levels were significantly associated with better OS in CRPC patients treated with androgen receptor-targeted agents (ARTAs) (pooled HR 0.64, 95[%] CI 0.55–0.75), but not in t